SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing massive volatility driven by rapid appreciation and speculation around its integration of music events with Web3 technology, fueling heated debate about whether it is a legitimate community-led project or a manipulated pump-and-dump scheme. While proponents highlight upcoming global event catalysts and a lack of token unlocks until late 2026, many vocal critics are pointing to allegations of supply concentration and market manipulation as reasons to approach the token with extreme caution.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can&nbsp;earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is drawing attention as market participants debate its long-term potential compared to Bitcoin, with many community members highlighting the protocol's fundamental strength and recent developments in DeFi lending. Traders are actively discussing technical support levels and potential bear traps while expressing optimism about its role in the broader altcoin sector as investors look for higher growth opportunities.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is seeing significant investor attention following a major policy catalyst, as the administration moves to fast-track clinical research pathways for psychedelic-based therapies. The community is actively debating the stock's potential for a re-rating based on these regulatory tailwinds, with ongoing discussions centered on upcoming late-stage clinical data, cash reserves, and speculative M&A sentiment.

Highstreet

Highstreet is experiencing high-volume volatility, with the community actively debating whether current price action represents a legitimate reversal and short squeeze potential or a cycle of pump-and-dump activity. Investors are closely monitoring its technical setup and whale accumulation patterns, though sentiment remains divided given the significant drawdown from its historical highs.

TokenOS is the world’s most advanced AI-powered Web3 development platform, designed to turn natural language prompts into fully functional, production-ready blockchain applications. From simple tokens and memecoins to complex DeFi protocols, TokenOS automates the creation, deployment, and auditing of smart contracts and dApps with enterprise-grade reliability. By combining advanced language models with blockchain infrastructure, TokenOS removes the barriers of technical expertise, making Web3 development accessible to everyone. With instant deployment, built-in security best practices, and cross-chain support on the roadmap, TokenOS empowers entrepreneurs, developers, and creators to launch tokenized businesses and decentralized applications in seconds.

TokenOS AI

TokenOS AI is gaining traction as a high-conviction micro-cap play within the AI sector, with community members emphasizing its long-term potential as a hidden gem on the Solana network. Discussions frequently compare its early-stage growth profile to more established AI compute projects, fueling speculation among retail investors looking for speculative opportunities.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending amid high volatility as conflicting reports regarding the status of the Strait of Hormuz create intense debate over geopolitical stability and energy security. The community is sharply divided between "bulls" expecting a supply-driven breakout and "bears" dismissing recent price action as a temporary relief rally within a broader downtrend.

PolySwarm

PolySwarm is capturing significant community attention as investors anticipate a potential breakout, driven by the project's cybersecurity utility, low circulating supply, and high-volume swings that keep it on the radar for speculative gains. Traders are actively debating the timing of an "alt season" while closely monitoring volume spikes and whale activity, which they hope will act as the catalyst to push the token toward higher resistance levels.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biohaven is currently trending as investors focus on a high-stakes Q4 PDUFA decision for its lead candidate, troriluzole, alongside active community discussions regarding the company's broader pipeline and potential for a late-year catalyst. Market sentiment remains cautious but attentive, with traders closely monitoring the firm's cash burn and recent analyst upgrades as they look for signs of a clear pathway for its orphan disease and epilepsy programs.

SAP SE engages in the provision of enterprise application software and software-related services. It operates through the following segments: Applications, Technology, and Support; Qualtrics; and Services. The Applications, Technology, and Services segment includes sale of software licenses, support offerings, and cloud subscriptions. The Qualtrics segment sells experience management cloud solutions. The Services segment offers professional services, premium support services, implementation services for software products, and education services on the use of products. The company was founded by Hasso Plattner, Klaus Tschira, Claus Wellenreuther, Dietmar Hopp, and Hans-Werner Hector on April 1, 1972 and is headquartered in Walldorf, Germany.

Sap SE - ADR

SAP AG

SAP is currently navigating significant market volatility as investors weigh strong enterprise demand against concerns over cloud backlog growth and the competitive landscape. While the company's aggressive shift toward AI-powered ERP solutions remains a central talking point, the community remains divided over whether its current valuation accurately reflects potential long-term cloud margins or if the sector is facing a broader pricing correction.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is surging on market excitement following a major executive order that prioritizes regulatory pathways for psychedelic therapies. The community is actively discussing the stock's potential for rapid clinical expansion and institutional re-rating as investors speculate on policy-driven tailwinds accelerating approval timelines.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Best Biotech Stocks To Consider - April 18th

Danaher, Moderna, Vertex Pharmaceuticals, United Therapeutics, Medpace, argenex, and Flag Ship Acquisition are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

Mirae Asset Global Investments Co. Ltd. Grows Holdings in Danaher Corporation $DHR

Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 41.8% during the 4th quarter, according to the company in its most recent 13F...

Danaher Corporation (NYSE:DHR) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Danaher Corporation (NYSE:DHR - Get Free Report) have received a consensus rating of "Moderate Buy" from the twenty-one ratings firms that are currently covering the company, MarketBeat...

<ul class="summary-bullets"><li>The dispute between the two firms began in 2021 when Masimo, which is being acquired by Danaher, accused Apple of poaching key engineers and stealing pulse-oximetry technology it had developed.</li><li>Masimo can appeal the ITC's decision to the Washington-based U.S. ​Court of Appeals for the Federal Circuit, Reuters noted.</li></ul>The U.S. International Trade Commission has ruled in favor of Apple (AAPL), rejecting medical-device maker Masimo’s (MASI) latest attempt to impose a fresh import ban on certain Apple Watch models.The commission closed Masimo’s case after declining to review a preliminary ruling issued in March by an ITC administrative law judge. The judge had found that Apple’s redesigned smartwatches do not infringe two Masimo patents covering blood-oxygen measurement technology.“For more than six years, Masimo has waged a relentless legal campaign against Apple, and nearly all of its claims have been rejected,” Apple reportedly said in a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/litigation/apple-defeats-bid-new-apple-watch-import-ban-us-trade-tribunal-2026-04-17/">statement</a> to Reuters while extending its gratitude to the commission.<h2 class="st-heading-2">Apple Vs. Masimo</h2>The dispute between the two firms began in 2021 when Masimo, which is being acquired by Danaher (DHR), accused Apple of poaching key engineers and stealing pulse-oximetry technology it had developed for hospital-grade monitors. Masimo claimed Apple used the know-how to launch the blood-oxygen feature on the Apple Watch. The Irvine, California-based company filed patent-infringement and trade-secret lawsuits in California federal court and a separate complaint at the U.S. International Trade Commission.In December 2023, the ITC sided with Masimo, imposing an import ban on Apple Watch Series 9 and Ultra 2 models that used the blood-oxygen sensor. Apple subsequently disabled the feature in America while it developed a redesign.Apple’s redesign was approved by the U.S. Customs and Border Protection in August 2025. However, Masimo challenged that redesign at the ITC, leading up to the events on Friday.Masimo can appeal the decision to the Washington-based U.S. ​Court of Appeals for the Federal Circuit, Reuters noted.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around MASI and AAPL stocks stayed within the ‘bullish’ territory at the time of writing.While <a href="https://stocktwits.com/symbol/MASI">MASI stock</a> has gained 17% over the past 12 months, <a href="https://stocktwits.com/symbol/AAPL">AAPL stock </a>has gained 37%.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-sparks-retail-buzz-ahead-of-aacr-presentation-on-experimental-cancer-therapy/cZJy282RIUY">SLS Stock Sparks Retail Buzz Ahead of AACR Presentation On Experimental Cancer Therapy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A new Apple Watch is displayed during an Apple special event at Apple headquarters on September 9, 2025 in Cupertino, California.  

Apple Clears Major Legal Hurdle After U.S. Trade Tribunal Shuts Down Masimo’s Latest Watch Ban Attempt

The U.S. International Trade Commission closed Masimo’s case after declining to review a preliminary ruling issued in March by an ITC administrative law judge. 

Equity

The U.S. International Trade Commission closed Masimo’s case after declining to review a preliminary ruling issued in March by an ITC administrative law judge. 


Top Biotech Stocks To Watch Now - April 17th

Danaher, United Therapeutics, and Vertex Pharmaceuticals are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that apply...

Danaher Corporation $DHR Stake Lifted by Whittier Trust Co.

Whittier Trust Co. increased its stake in Danaher Corporation (NYSE:DHR - Free Report) by 12.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange...

KBC Group NV Has $65.13 Million Stock Holdings in Danaher Corporation $DHR

KBC Group NV boosted its stake in Danaher Corporation (NYSE:DHR - Free Report) by 6.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission...

Lbp Am Sa Purchases 46,347 Shares of Danaher Corporation $DHR

Lbp Am Sa grew its position in Danaher Corporation (NYSE:DHR - Free Report) by 422.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The...

Fisher Funds Management LTD Has $91.23 Million Stock Position in Danaher Corporation $DHR

Fisher Funds Management LTD lessened its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 26.0% in the fourth quarter, according to the company in its most recent 13F filing with...

Danaher Corporation (NYSE:DHR) Short Interest Up 25.0% in March

Danaher Corporation (NYSE:DHR - Get Free Report) saw a large growth in short interest in March. As of March 31st, there was short interest totaling 6,939,368 shares, a growth of 25.0% from the March...

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, and Diagnostics. The Biotechnology segment includes bioprocessing, discovery, and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Current Price	$194.75
Prev Close	$193.78
Open	$194.58
Dividend Yield	0.56%
50-Day Moving Average	$199.39
Beta	0.87
Avg. Volume	4.13M
PE Ratio	38.56

52-Week High	$242.80
52-Week Low	$180.03
Market Capitalization	$137.82B
EPS (Annual)	$5.05
Price to Book	2.62
Revenue Per Employee	$409,466.67

DHR
Danaher Corp.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DHR News

DHRDanaher Corp.